Last reviewed · How we verify
Advancis Pharmaceutical Corporation — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Amoxicillin Pulsatile Release Multiparticluate Sprinkle | Amoxicillin Pulsatile Release Multiparticluate Sprinkle | phase 3 | Beta-lactam antibiotic (penicillin) | Penicillin-binding proteins (PBPs) | Infectious Disease |
Therapeutic area mix
- Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Advancis Pharmaceutical Corporation:
- Advancis Pharmaceutical Corporation pipeline updates — RSS
- Advancis Pharmaceutical Corporation pipeline updates — Atom
- Advancis Pharmaceutical Corporation pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Advancis Pharmaceutical Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/advancis-pharmaceutical-corporation. Accessed 2026-05-17.